Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer
October 03 2016 - 8:15AM
Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a
clinical-stage pharmaceutical company discovering and developing
targeted therapeutics in disease areas of inflammation and
immuno-oncology, is pleased to announce the appointment of Dr.
Barbara Troupin, M.D. as Chief Medical Officer and Vice President,
Clinical Development. Dr. Troupin will lead overall clinical
and medical affairs strategies for Aquinox’s ongoing programs
as well as future development and potential commercialization
plans.
Over more than 18 years Dr. Troupin has led clinical development
and strategy at multiple, leading clinical research institutions
and within the therapeutic drug development sector. Dr. Troupin
most recently served as Senior Vice President and Chief Medical
Officer at Apricus Bioscience, Inc. where she led the development
and execution of clinical strategy for three drug development
programs ranging from proof-of-concept to NDA filing, including
Vitaros for the treatment of erectile dysfunction. Prior to
Apricus, Dr. Troupin held the role of Vice President in Medical
Affairs at VIVUS, Inc. where she led risk evaluation and mitigation
strategy for Qsymia to treat weight loss, while also building
relationships with thought leaders and key opinion leaders (KOLs).
Dr. Troupin received her Doctorate in Medicine in 1995 from the
University of Pennsylvania School of Medicine where she also
completed her Master’s in Business Administration, with an emphasis
in health care management, from the Wharton School of Business.
“Barbara brings a proven track record of building KOL and
patient advocacy relationships, defending regulatory submissions,
and overall success in clinical strategy,” said David Main,
President & CEO of Aquinox. “Barbara joins at an ideal time for
contributing medical and clinical leadership to our recently
initiated Leadership 301 phase 3 clinical trial with AQX-1125 in
Interstitial Cystitis/Bladder Pain syndrome (IC/BPS) as well as for
guiding our clinical expansion and supporting our potential
partnering and commercial preparations.”
About Interstitial Cystitis/Bladder Pain Syndrome
(IC/BPS)
IC/BPS is a chronic inflammatory bladder disease characterized
by pelvic pain and increased urinary urgency and/or frequency. For
many sufferers, these symptoms are severe and adversely affect all
major aspects of their lives, including overall physical and
emotional health, employment, social and intimate relationships,
and leisure activities. While the cause of the disease remains
largely unknown, erosion of the bladder lining is thought to be a
significant contributor. IC/BPS is estimated to affect millions of
people in the United States and around the world. Most IC/BPS
patients continue to suffer this debilitating condition, despite
treatment with existing therapies. Most current therapies and those
in development are focused solely on symptomatic relief of IC/BPS.
Aquinox believes new and innovative therapies that target the
underlying disease in order to reduce the chronic pain and urinary
symptoms are needed.
About AQX-1125
AQX-1125, Aquinox’s lead drug candidate, is a small molecule
activator of SHIP1, which is a regulating component of the PI3K
cellular signaling pathway. By increasing SHIP1 activity, AQX-1125
accelerates a natural mechanism that has evolved to maintain
homeostasis of the immune system and reduce immune cell activation
and migration to sites of inflammation. AQX-1125 has demonstrated
preliminary safety and favorable drug properties for once daily
oral administration in multiple preclinical studies and seven
completed clinical trials.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical
company discovering and developing targeted therapeutics in disease
areas of inflammation and immuno-oncology. Aquinox’s lead drug
candidate, AQX-1125, is a small molecule activator of SHIP1
suitable for oral, once daily dosing. With a successful Phase 2
clinical trial completed in 2015, Aquinox initiated a Phase 3 trial
in 2016 (LEADERSHIP 301) with AQX-1125 for treatment of IC/BPS in
August of 2016. Aquinox has a broad intellectual property portfolio
and pipeline of preclinical drug candidates that activate SHIP1.
For more information, please visit www.aqxpharma.com.
Cautionary Note
on Forward-looking
Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to potential
commercialization of, and market opportunities for, AQX-1125. These
statements are subject to risks and uncertainties that could cause
actual results and events to differ materially from those
anticipated, including, but not limited to, risks and uncertainties
related to: our ability to enroll patients in our clinical trials
at the pace that we project; as an organization, we have never
conducted a pivotal clinical trial before; the size and growth of
the potential markets for AQX-1125 or any future product candidates
and our ability to serve those markets; our ability to obtain and
maintain regulatory approval of AQX-1125 or any future product
candidates; reaching agreement on design of pivotal trials with
regulatory authorities and our expectations regarding the potential
safety, efficacy or clinical utility of AQX-1125 or any future
product candidates. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. More information about the risks and uncertainties
faced by Aquinox is contained in the company's Quarterly Report on
Form 10-Q for the quarter ended June 30, 2016 filed with the
Securities and Exchange Commission. Aquinox disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Contact
Info:
Brendan PayneSenior Manager, Investor Relations
Aquinox Pharmaceuticals,
Inc.604.901.3019ir@aqxpharma.com
Gitanjali Ogawa Vice President
The Trout
Group646-378-2949Gogawa@troutgroup.com
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Apr 2024 to May 2024
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From May 2023 to May 2024